Status:
UNKNOWN
Effect of Rosuvastatin in Abdominal Sepsis
Lead Sponsor:
Universidad Autonoma de San Luis Potosí
Conditions:
Sepsis
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether rosuvastatin is effective as a coadjuvant drug in the integral management of abdominal sepsis acknowledged by surgery.
Detailed Description
The sepsis is often lethal, the mortality's ranks are identified among 25 to 70%, this depends on definition, severity and co-morbidities. The number of deaths by sepsis could be similar to myocardial...
Eligibility Criteria
Inclusion
- Man or women \> 18 and \< 80 years old with abdominal sepsis, confirmed diagnosis by surgery of broad peritonitis before 48 hours in progression
- Injury by steel or firearm with contaminated abdominal cavity
- APACHE II major or equal than 8
- Acceptance to be included
Exclusion
- Ingestion of: fibrates, niacin, cyclosporin, azoles, macrolides, inhibitors of protease, nefazodone, verapamil, diltiazem, amiodarone
- Hypovolemic shock III and IV after get surgery
- Cardio-respiratory failure pre or trans surgery
- Allergy to used drug
- Use previous of statin
- Hepatopathy or myopathy and(or) history, hepatic failure (Child B y C)
- Management in other Hospital
- Pregnancy
- Thoracic injury, head injury (moderate and severe), multiple fractures or with bone exposition, rectal injury
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2011
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00357123
Start Date
August 1 2006
End Date
September 1 2011
Last Update
February 21 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Central "Dr. Ignacio Morones Prieto
San Luis Potosí City, San Luis Potosí, Mexico, 78240